{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:15:56Z","timestamp":1790727356412,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1124\/dmd.113.052662","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T04:47:09Z","timestamp":1378270029000},"page":"2066-2075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Heterotropic Activation of the Midazolam Hydroxylase Activity of CYP3A by a Positive Allosteric Modulator of mGlu5: In Vitro to In Vivo Translation and Potential Impact on Clinically Relevant Drug-Drug Interactions"],"prefix":"10.1016","volume":"41","author":[{"given":"Anna L.","family":"Blobaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank W.","family":"Byers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Turlington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margrith E.","family":"Mattmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Lavreysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Bartolom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor J.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun R.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.052662_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.pharmtox.45.120403.100004","article-title":"Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions","volume":"45","author":"Atkins","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.052662_bib2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/tx0600090","article-title":"Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites","volume":"19","author":"Avent","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.113.052662_bib3","first-page":"515","article-title":"Potential induction of CYP3A4 after a single dose of efaverinz using midazolam pharmacokinetics as a marker (Abstract 59)","volume":"104","author":"Bayer","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.052662_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/dmd.113.052662_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FBP.0b013e3282feb0ac","article-title":"Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm","volume":"19","author":"Darrah","year":"2008","journal-title":"Behav Pharmacol"},{"key":"10.1124\/dmd.113.052662_bib6","doi-asserted-by":"crossref","first-page":"6797","DOI":"10.1074\/jbc.M111.325654","article-title":"Peripheral ligand-binding site in cytochrome P450 3A4 located with fluorescence resonance energy transfer (FRET)","volume":"287","author":"Davydov","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.113.052662_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0022-3565(24)39272-9","article-title":"Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity","volume":"293","author":"Domanski","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052662_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/abbi.1997.0525","article-title":"Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation","volume":"350","author":"Domanski","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.113.052662_bib9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1124\/jpet.104.078519","article-title":"Predictive models of CYP3A4 Heteroactivation: in vitro-in vivo scaling and pharmacophore modeling","volume":"312","author":"Egnell","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052662_bib10","first-page":"1638","article-title":"In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes","volume":"29","author":"Fang","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.052662_bib12","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1208\/aapsj080112","article-title":"Cytochrome P450s and other enzymes in drug metabolism and toxicity","volume":"8","author":"Guengerich","year":"2006","journal-title":"AAPS J"},{"key":"10.1124\/dmd.113.052662_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/clpt.2009.206","article-title":"Effect of simultaneous induction and inhibition of CYP3A by St John\u2019s Wort and ritonavir on CYP3A activity","volume":"87","author":"Hafner","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052662_bib14","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1073\/pnas.95.12.6636","article-title":"Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics","volume":"95","author":"Harlow","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.113.052662_bib15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1124\/dmd.108.021279","article-title":"Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications","volume":"36","author":"Henshall","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib16","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1021\/bi992765t","article-title":"Elucidation of distinct ligand binding sites for cytochrome P450 3A4","volume":"39","author":"Hosea","year":"2000","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.113.052662_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0928-0987(01)00144-0","article-title":"Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone","volume":"14","author":"Hutzler","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.113.052662_bib18","first-page":"1029","article-title":"Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model","volume":"29","author":"Hutzler","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1124\/dmd.30.4.355","article-title":"Atypical kinetic profiles in drug metabolism reactions","volume":"30","author":"Hutzler","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib20","first-page":"51","article-title":"Predicting drug-drug interactions in drug discovery: where are we now and where are we going?","volume":"8","author":"Hutzler","year":"2005","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1124\/dmd.113.052662_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.abb.2005.02.027","article-title":"Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity","volume":"438","author":"Jushchyshyn","year":"2005","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.113.052662_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/dmd.31.3.243","article-title":"Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway","volume":"31","author":"Kalgutkar","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib23","first-page":"1644","article-title":"Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism","volume":"29","author":"Kenworthy","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.111.043844","article-title":"Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1\u2032-hydroxylation in vitro","volume":"40","author":"Keubler","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0026-895X(24)12112-8","article-title":"Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation","volume":"61","author":"Khan","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.113.052662_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/jpet.104.079244","article-title":"A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models","volume":"313","author":"Kinney","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052662_bib27","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/jps.21121","article-title":"Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates","volume":"97","author":"Komura","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.113.052662_bib28","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1021\/bi9715627","article-title":"Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites","volume":"37","author":"Korzekwa","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.113.052662_bib29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1124\/jpet.102.035972","article-title":"In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat","volume":"302","author":"Kotegawa","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052662_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.113.052662_bib31","first-page":"1150","article-title":"Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes","volume":"25","author":"Lee","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.113.052662_bib33","first-page":"368","article-title":"Substrate inhibition kinetics for cytochrome P450-catalyzed reactions","volume":"29","author":"Lin","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.108.136580","article-title":"ADX47273 [S-(4-fluoro-phenyl)-3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities","volume":"327","author":"Liu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052662_bib35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1124\/dmd.107.014910","article-title":"CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis","volume":"35","author":"Locuson","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s002280050733","article-title":"Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors","volume":"56","author":"Mart\u00ednez","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052662_bib37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00213-004-1792-z","article-title":"Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia","volume":"174","author":"Moghaddam","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.113.052662_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0090-9556(24)15184-7","article-title":"Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine","volume":"28","author":"Ngui","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.052662_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/clpt.2011.182","article-title":"Heterotropic effects on drug-metabolizing enzyme activities: in vitro curiosity emerges as a clinically meaningful phenomenon (perhaps?)","volume":"91","author":"Obach","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052662_bib41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0022-3565(24)35332-7","article-title":"Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms","volume":"292","author":"Perloff","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052662_bib42","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1021\/bi300894z","article-title":"Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules","volume":"51","author":"Shah","year":"2012","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.113.052662_bib43","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/bi00187a009","article-title":"Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site","volume":"33","author":"Shou","year":"1994","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.113.052662_bib44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1042\/bj3400845","article-title":"Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives","volume":"340","author":"Shou","year":"1999","journal-title":"Biochem J"},{"key":"10.1124\/dmd.113.052662_bib45","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0022-3565(24)35211-5","article-title":"Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism","volume":"291","author":"Tang","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052662_bib46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.38.1.389","article-title":"In vitro and in vivo drug interactions involving human CYP3A","volume":"38","author":"Thummel","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.052662_bib47","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1124\/dmd.109.029397","article-title":"Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam","volume":"37","author":"van Waterschoot","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0090-9556(24)15374-3","article-title":"Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent","volume":"28","author":"Wang","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052662_bib49","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1099736","article-title":"Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone","volume":"305","author":"Williams","year":"2004","journal-title":"Science"},{"key":"10.1124\/dmd.113.052662_bib50","doi-asserted-by":"crossref","first-page":"27438","DOI":"10.1074\/jbc.271.44.27438","article-title":"Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4\/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5","volume":"271","author":"Yamazaki","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.113.052662_bib51","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/tx400008g","article-title":"In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice","volume":"26","author":"Yamazaki","year":"2013","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.113.052662_bib52","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/clpt.2011.178","article-title":"Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam","volume":"91","author":"Yang","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052662_bib53","doi-asserted-by":"crossref","first-page":"38091","DOI":"10.1074\/jbc.C400293200","article-title":"The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution","volume":"279","author":"Yano","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.113.052662_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpba.2008.05.011","article-title":"An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS\/MS end-point","volume":"48","author":"Youdim","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.113.052662_bib55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/bi301567z","article-title":"Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis","volume":"52","author":"Zhang","year":"2013","journal-title":"Biochemistry"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.052662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:39:04Z","timestamp":1739907544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624115528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0090955624115528"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.052662","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterotropic Activation of the Midazolam Hydroxylase Activity of CYP3A by a Positive Allosteric Modulator of mGlu5: In Vitro to In Vivo Translation and Potential Impact on Clinically Relevant Drug-Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.052662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}